Behind the Miracle Therapies of Neuroscience

How NeuroOne partnered with the Mayo Clinic to modernize this giant $13.6 billion market.


NASDAQ: NMTC

Build your watchlist with us

Get the latest stock ideas direct to your inbox. 100% free and your information stays with us.

5 Stimulating Reasons to Add NeuroOne (NASDAQ: NMTC) to Your Watchlist

  • Today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain’s neural connections.


  • The diagnostic electrode technology currently used to detect neurological disorders is the same that was developed way back in the 1960s.


  • Mayo Clinic began testing NeuroOne’s technology in preclinical models and clinical research in 2015 and is presently a top shareholder.


  • NeuroOne Evo electrode product line is complementary to Zimmer Biomet’s ROSA ONE Brain platform used in minimally invasive neurosurgeries.


  • NeuroOne has received FDA-approval for their Evo Cortical and sEEG Electrodes.


We live in an age of amazing medical breakthroughs—advances so remarkable that doctors really can make the blind see. They can even revive folks struck by lightning or ones who’ve slipped into a coma.


Front and center of all this is neuroscience, dubbed the next great frontier in medicine.

Now here’s what’s even more amazing. Our smartphones have better technology than the tech that sent man to the moon.


So why is the diagnostic electrode technology being used today the same as what was developed way back in the 1960s?

This could be slowing down life-saving progress and setting scientific advances back years.

NeuroOne: Driving the Shift from Science Fiction to Science Fact

This innovative company is behind the scenes bringing what once could be considered science-fiction-inspired technologies to the brink of creation or they already have it in development.


And thanks to NeuroOne’s strategic partnerships they expect their technologies to be widely adopted in the near future.

The Future of Neuroscience is Built on This Thin Film Electrode Technology

The company is developing and perfecting high-definition, minimally invasive Evo® Cortical Electrodes for the diagnosis and treatment of various neurological conditions.


Used in electrocorticography (ECoG) or intracranial electroencephalography (iEEG) surgeries, these wafer-thin electrodes will help record, monitor, and stimulate the surface of the brain for up to 30 days.


So what does that all mean?


In simple terms, compared to current technologies, Evo Electrodes are designed to reduce trauma to the brain by allowing a less invasive, thinner, and flexible implant.

This incredible resource-efficient design:

  • Is over 7x thinner than today’s silicone electrode

  • Helps reduce post-surgery pain and swelling

  • Creates sharper EEG readings with less noise

  • Allows for smaller incisions where the electrodes simply slide in

  • Features disposable cables for a much safer, sterile environment

Opening the Door to Breakthrough Medical Advances

Here’s the fantastic part, this thin-film technology allows a much more immersive experience by significantly increasing the resolution of brain recordings.


This one technology alone opens the door to the use of powerful computing techniques, such as machine learning and artificial intelligence.

This machine learning can help:

  • Predict illnesses and treatments
  • Forecast health risks to various populations of people
  • Assist with healthcare records and workflow
  • Differentiate between tumors and healthy anatomy
  • Aid in drug development, lowering costs
  • Identify opportunities for clinical trials
  • Detect gaps in healthcare
  • Assist pathologists to make faster and more accurate diagnosis


Two FDA-Cleared Devices and Counting

Are you beginning to understand that NeuroOne is not just “another” MedTech company? In fact, their Evo Cortical and sEEG Electrodes are both FDA approved!

What they are doing right now has incredible implications for the future of the medical industry.

So much so that the technologies below could be commonplace and in wide use across the globe.

NeuroOne: Empowered by Two Outstanding Partners to Completely Disrupt the Old Paradigm

Innovation is coming and it’s coming fast. NeuroOne has developed strategic partnerships with the world-famous Mayo Clinic and Zimmer Biomet (NYSE: ZBH) to completely help modernize neurological study and treatments with their breakthrough film-thin electrodes.


And if this sounds a little nerdy to you. This part won’t…


The company could leverage its partnerships to become a leader in the Neurostimulation Devices Market projected to be worth a staggering $13.6 billion.


This could create an opportunity in that market like we’ve never seen before!

NeuroOne: A Direct Pipeline to the Largest and Most Comprehensive Neurological Practices in the World

How big is a partnership with the Mayo Clinic? Let’s just say game changing.


Mayo Clinic began testing NeuroOne’s technology in preclinical models and clinical research in 2015, invested in the Company in 2017, and is presently a top shareholder.


Here’s why this is so important to shareholders. Mayo Clinic offers the latest in neurological care with innovative therapies, new techniques and clinical trials developed by world-class experts. Their neurological team helps more than 100,000 adults and children each year, including those with complex or rare conditions.


Their neuroscientists constantly seek new knowledge to improve diagnosis and treatments for people with brain, spine, and nervous system disorders. Their many projects include:

  • Studying sleep-disordered breathing, narcolepsy
  • Restless legs syndrome
  • Insomnia
  • Electrical stimulation to stop seizures and epilepsy


With a 73,000-person workforce, Mayo Clinic cares for more than 1.3 million people each year with serious or complex illnesses from all 50 U.S. states and 130 countries.


Pretty impressive partner to have in one’s corner, don’t you think?

Why This Massive Portfolio Could Be The Key To Surge’s Future Success

Mining and exploration can be an extremely difficult, cost-intensive, and unpredictable business.

New mines can cost a fortune to discover and develop. They can take years and require support & help from host governments. And even after all that investment, fluctuations in metal prices can still wreak havoc on operations.

With these five projects, and the hundreds of claims contained within, Surge Battery Metals has a nearly unrivaled level of flexibility and freedom when it comes to both exploration and subsequent mining.

Depending on prevailing market conditions and early exploration results, the company could prioritize individual sites, then use the windfall to fund further development in other metals.

This level of freedom would also allow the company to potentially spin off successful mining projects for acquisition, in turn funding future development and mining.

All of this is in stark contrast to the state of many micro-cap mining & exploration companies, which are often just connected to a single property or jurisdiction that may (or may not) ever pay out.

Get the latest stock ideas direct to your inbox.

100% free and your information stays with us.

NeuroOne: How Zimmer Biomet Could Help NeuroOne Grab an Ever-Bigger Chunk of the Market

In July 2020, NeuroOne entered into an exclusive development and distribution agreement in with Zimmer Biomet, one of the world’s most highly respected medical device manufacturers.


The Evo electrode product line is complementary to Zimmer’s ROSA ONE Brain platform used in minimally invasive neurosurgeries.

In late September 2021 the company announced that it successfully completed an animal feasibility study of its combination recording and ablation technology at T3 Labs and Georgia State/Georgia Tech Center for Advanced Brain Imaging in Atlanta Georgia under the guidance of Dr. Robert Gross of Emory University.


The study evaluated the ability of the NeuroOne Evo® sEEG electrodes to record brain activity and then ablate (remove) brain tissue using radiofrequency thermocoagulation in a porcine model.


The product is designed to provide the ability to both identify problematic areas of the brain causing seizures as well as ablate brain tissue to alleviate these symptoms.


This would represent a major advancement in neurosurgery, given that patients must first undergo the diagnostic surgery and then schedule a future second surgery to ablate the problematic tissue.


The Evo ablation electrode represents the Company’s first development effort for therapeutic technology and is expected to be the next product offering in its portfolio pending FDA clearance.


In the history of medical advancements, each new device may lead what could be considered the biggest combined market targeted by a single company.

NeuroOne: Financially Sound with Exceptional Forecasted Revenues

While all these technologies are amazing, cool, and plausibly lifesaving, it’s just as important to take back and look at the big picture.


We’re talking about financial position. According to SimplyWall Street, NMTC is looking great from that perspective.


The company’s short-term assets are nearly 7x their short-term obligations. Better still they far outweigh their long-term obligations.

Now here’s a really positive outlook for the company. According to SimplyWall Street, NMTC’s revenue (41.1% per year) is forecast to grow faster than the US market (9.1% per year).


But it gets even better. NMTC’s revenue (41.1% per year) is forecast to grow faster than 20% per year.

For the cherry on top of the cake, as of Feb. 3, 2022, NMTC outperformed the market and their industry over an extremely volatile 7-day stretch.

At least for the moment – this company is at $2 per share. If things continue to progress as they have been, this company could become one of those “I told you so” stories with a sky-high price to match based on potential catalysts laid out in this report.


Plus, their revolutionary new devices could help the $13.6 billion neurostimulation devices market eliminate chronic pain and depression once and for all.

5 Stimulating Reasons to Add NeuroOne (NASDAQ: NMTC) to Your Watchlist

  • Today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain’s neural connections.

  • The diagnostic electrode technology currently used to detect neurological disorders is the same that was developed way back in the 1960s.

  • Mayo Clinic began testing NeuroOne’s technology in preclinical models and clinical research in 2015 and is presently a top shareholder.

  • NeuroOne Evo electrode product line is complementary to Zimmer Biomet’s ROSA ONE Brain platform used in minimally invasive neurosurgeries.


  • NeuroOne has received FDA-approval for their Evo Cortical and sEEG Electrodes.

NeuroOne: A Direct Pipeline to the Largest and Most Comprehensive Neurological Practices in the World

How big is a partnership with the Mayo Clinic? Let’s just say game changing.


Mayo Clinic began testing NeuroOne’s technology in preclinical models and clinical research in 2015, invested in the Company in 2017, and is presently a top shareholder.


Here’s why this is so important to shareholders. Mayo Clinic offers the latest in neurological care with innovative therapies, new techniques and clinical trials developed by world-class experts. Their neurological team helps more than 100,000 adults and children each year, including those with complex or rare conditions.


Their neuroscientists constantly seek new knowledge to improve diagnosis and treatments for people with brain, spine, and nervous system disorders. Their many projects include:

  • Studying sleep-disordered breathing, narcolepsy
  • Restless legs syndrome
  • Insomnia
  • Electrical stimulation to stop seizures and epilepsy


With a 73,000-person workforce, Mayo Clinic cares for more than 1.3 million people each year with serious or complex illnesses from all 50 U.S. states and 130 countries.


Pretty impressive partner to have in one’s corner, don’t you think?

Sources

Source 1: https://www.gminsights.com/pressrelease/neurostimulation-devices-market-size

Source 2: https://n1mtc.com/investors

Source 3: https://www.healthaffairs.org/doi/10.1377/hlthaff.2020.01118

Source 4: https://n1mtc.com/technology.html

Source 5: https://builtin.com/artificial-intelligence/machine-learning-healthcare

Source 6: https://www.mpo-mag.com/contents/view_breaking-news/2021-12-08/fda-clears-neuroone-medical-technologies-evo-seeg-electrode/

Source 7: https://seekingalpha.com/article/4470806-neuroone-nmtc-stock-thin-film-electrodes-neurological-conditions

Source 8: https://www.mayoclinic.org/departments-centers/neurology/home/orc-20117057

Source 9: https://www.mayoclinic.org/about-mayo-clinic

Source 10: https://www.yahoo.com/now/neuroone-medical-technologies-corporation-announces-130000582.html

Source 11: https://simplywall.st/stocks/us/healthcare/nasdaq-nmtc/neuroone-medical-technologies

Disclaimer

Stock Research Today is a project of Dadmin Capital LLC and intended solely for entertainment and informational purposes. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/. This website / media webpage is owned, operated and edited by Dadmin Capital LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Dadmin Capital” refers to Dadmin Capital LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage .We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Dadmin Capital business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Dadmin Capital. often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Compensation – Pursuant to an agreement between Dadmin Capital LLC and TD Media LLC, Dadmin Capital LLC has been hired for a period beginning on 2/8/22 and ending after 2 business days to publicly disseminate information about (NASDAQ: NMTC) via digital communications. We have been paid seven thousand five hundred USD via ACH Bank Transfer. Social Media Compensation – Pursuant to an agreement between Dadmin Capital LLC and Social Media Outlet, Dadmin Capital LLC has hired Social Media Outlet for a period beginning on 2/1/22 and ending after one business day to publicly disseminate information about (NASDAQ: NMTC) via digital communications. We have paid this Social Media Outlet one thousand USD via ACH Bank Transfer.